Board of Directors

Dr. Waxmonsky is the Division Chief of Child Adolescent Psychiatry at the Hershey Medical Center, the University Chair in Child Psychiatry at Penn State and Professor of Psychiatry at the Penn State College of Medicine. He completed medical school and general psychiatry residency training at SUNY Buffalo and child fellowship at MGH. Over the past 20 years, he has worked in academics, with a clinical, research and teaching focus on ADHD. His research centers on the integration of medication and behavioral interventions targeting both children and their parents to improve the efficacy and tolerability of ADHD treatments. He has published over 90 peer reviewed articles or book chapters and served as a PI or CoI on over 40 different research trials with funding from NIH, industry and private foundations. He was recently awarded the AACAP Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder for his study examining the growth effects of CNS stimulants. He runs a clinical practice that provides assessment, psychosocial and pharmacological treatment services for ADHD across the lifespan. He also serves as a regional medical director for Pennsylvania’s Child Psychiatry Access Program where he has studied efforts to improve engagement with ADHD treatments in the primary care setting.  

As a member of APSARD and a conference attendee, I have always been impressed the breadth of international expertise from academia, industry and the community who come together through APSARD to expand the evidence base for the assessment and treatment of ADHD across the lifespan.

I am a psychiatrist who has spent much of his career working with those affected by attention deficit hyperactivity disorder.  I trained in the United Kingdom and had the opportunity to work in one of the first clinical assessments centers for adult ADHD.  An awareness of the gaps in our clinical knowledge led me to pursue research and I moved to the United States to work at the NIMH.  Here, I participated in studies examining the neural differences that are associated with ADHD.  My recent research focus has been on the genomic, neural and cognitive features that are associated with persistence of ADHD symptoms from childhood into adulthood. I am particularly interested in working with clinical colleagues to build a research agenda that better meets the needs of those with ADHD. 

I grew up with a typical ADHD story. I did very well in school but never learned to study. Luckily, I was a nice kid, well liked, never got into trouble; so I got by. High school was harder because I didn’t know how to do the work.  I very nearly flunked out of college.  Since all I had ever wanted to be was a doctor, and that was unlikely; I got my Mrs. and took a clerical job. 

Three years later (1973), an article in Ms. Magazine called The New Nursing, got my career started. Suddenly, there was a career for me, nursing, and it was in the real world of public health. I felt very lucky. I was doing well in school again and loved it. 

When my kids got old enough, and with a gentle push from my mother, I went for my Masters in Pediatric Nursing and, in 1993, started my first job as a Nurse Practitioner in Pediatric Neurology. It was there that I first heard of ADHD. Even in Pediatrics, it was never mentioned in school. What an eye-opener it was, having my lifelong difficulties finally explained. 

My love for working with ADHD patients and their parents, made me a specialist in 1995. Then, with a gentle push from my collaborating physician, I started a private practice in 1997. 

In 2003, I went back to school to earn my degree in Psychiatric Nursing; and this time I didn’t need a push. I was driven to learn about the treatment of more complicated ADHD patients and to expand my practice to include adults. It was an exciting time in my career.  Despite this, it was overall disappointing. Given the prevalence of ADHD and the frequency of comorbidity; it shocked me when I saw how many psychiatric providers don’t even look for underlying ADHD before treating symptoms of anxiety or depression. It still baffles me that so many psychiatric practitioners haven’t figured out that life with ADHD is hard, which frequently leads to sadness and worry. In these circumstances, ADHD should always be ruled out, as I have impressed on my NP students over the past 10 years.   

I have grown in clinical expertise by regular attendance at programs like MGH’s ADHD Across the Lifespan, and by participating in the CHADD annual conference and APSARD meetings. I have particularly enjoyed giving my presentation on medication delivery systems.  In fact, it was at a CHADD conference about 10 years ago that Russell Barkley introduced me to APSARD. I was grateful to finally find a professional group that spoke my language.

Erin Schoenfelder Gonzalez, Ph.D., is an Associate Professor in the Department of Psychiatry and Behavioral Sciences and Adjunct Associate Professor in the Department of Pediatrics at the University of Washington School of Medicine. She is a practicing clinical psychologist at Seattle Children’s Hospital in the Program to Enhance Attention Regulation and Learning (PEARL Clinic). Her specialization and research interests include parent-directed behavioral treatments for ADHD and the association of ADHD with health risk behaviors, especially physical activity and screen use.

As a member since 2015, I have benefited greatly from connecting and sharing knowledge through the APSARD community and appreciate the opportunity to contribute to the future of the organization.  In particular, I am excited to promote early career opportunities for new members, highlight issues of equity and access in the ADHD treatment, and continue to grow APSARD’s focus on child and family health promotion.

My name is Margaret (Maggie) Sibley, Ph.D. and I am an Associate Professor of Psychiatry & Behavioral Sciences at the University of Washington School of Medicine and a researcher and psychologist Seattle Children’s Hospital. My research focuses on longitudinal trajectories of ADHD and their implication for clinical diagnosis in individuals age 12 and older. I also conduct National Institute of Mental Health and Institute of Education Sciences-funded work on adapting evidence-based interventions for ADHD to under-resourced school and community contexts. I serve on the professional advisory board of CHADD, the editorial advisory board of Attention magazine, and the program planning committee of APSARD. I am a junior member of the MTA Cooperative Group and the author of a book on treating ADHD in adolescents (2016, Guilford Press). I am passionate about team science and cross-cultural collaboration, innovative methods to promote design quality in research, and offering research mentorship to junior colleagues.

I am Professor of Psychiatry and Behavioral Sciences and of the MIND Institute at the University of California, Davis. I direct the Attention, Impulsivity, Regulation (AIR)/ADHD Program at the UC Davis MIND Institute. My work is translational in nature where I use cognitive neuroscience and behavior analytic principles to investigate attention, impulsivity and hyperactivity in children, adolescents, and adults in typical development and in ADHD. I conducted some of the earliest studies of functional neuroimaging in adults with ADHD, particularly in working memory, starting in the early 1990s. I currently apply fMRI, diffusion tension imaging (DTI), eye-tracking, behavioral and clinical measures in my research. For several years, I have been testing and developing tech-based interventions, including game play and virtual reality technology geared toward improving attention and self-control in individuals with ADHD and disorders with elevated rates of ADHD symptoms (e.g., autism, Fragile X). My goal is to develop targeted, precision health interventions, based on the neuroscience findings of ADHD and other relevant factors (e.g., community, developmental period, etc.). I have been awarded several grants from NIH and other federal agencies for my work in ADHD, autism and substance use disorders.

I am also active in training translational scientists across UC Davis and its NIH-funded Clinical and Translational Science Center (CTSC) where I direct the Mentored Clinical Research Training Program (MCRTP), the Mentoring Academy for Research Excellence (MARE) program and serve as associate director for the NIH-funded TL1 (i.e., T32) pre- and post-doctoral training program and team science endeavors in clinical and translational research. My work in this realm includes involvement in workforce development for translational science in national endeavors through the NIH National Center for Advancing Translational Science (NCATS) network.

I am motivated to serve on the APSARD Board of Directors as this is the leading organization bringing scientists, clinicians and other critical stakeholders together to further the science and care of persons with ADHD with evidence-base practices. APSARD fills an essential gap in advancing the scientific needs, advocacy and training of stakeholders to address the needs of the ADHD population, which has received less attention than is warranted given the high prevalence of ADHD and the myriad of challenges encountered by their families. I will work to continue to raise awareness in the scientific, professional, and lay community about the importance of advancing ADHD science and the education of its stakeholders. I bring to the Board my personal experience in working with diverse disciplines and scientists (e.g., neuroscience, behavior analysis, epidemiology, computer science, biomedical engineering, etc.) and team science principles to advance how we study ADHD. This includes bringing in scientists in areas not typically involved in ADHD to participate in APSARD activities. Finally, I have a lengthy history of developing formal mentoring programs, focused on enhancing relationships between mentors and mentees and pleased to offer my expertise in this area.